Clinical Trial

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

Study acronym: PTCA199-16
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of anti-diabetic treatment on improving the overall survival for metastatic pancreatic cancer patients complicated by diabetes receiving gemcitabine and nab-paclitaxel chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-26.
Trial Details
NCT Number NCT07272109
Lead Sponsor Fudan University
Conditions Pancreatic Cancer
Enrollment 210 participants
Start Date 2026-01-01
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-15